<DOC>
	<DOCNO>NCT00040547</DOCNO>
	<brief_summary>The purpose study determine safety tolerability oral Farnesyl Protein Transferase Inhibitor ( SCH 66336 ) give combination intravenous docetaxel cancer patient advance solid tumor .</brief_summary>
	<brief_title>Farnesyl Protein Transferase Inhibitor ( FPTI ) Combination With Docetaxel Advanced Solid Tumors ( Study P01964 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Inclusion : Male Female Measurable evaluable disease No 2 prior chemotherapy regimen . Age great equal 18 . Karnofsky Performance Status great equal 70 % . Meets protocol requirement specify laboratory value . No manifestation malabsorption syndrome . Written inform consent cooperation patient Appropriate use effective contraception childbearing potential . Exclusion : Acute chronic leukemia multiple myeloma . Evidence 2 active malignancy , expect situ adequately treat basal squamous cell skin cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Cancer-Advanced Solid Tumors</keyword>
</DOC>